Morbidity and mortality in systemic lupus erythematosus during a 10-year period -: A comparison of early and late manifestations in a cohort of 1,000 patients

被引:989
作者
Cervera, R
Khamashta, MA
Font, J
Sebastiani, GD
Gil, A
Lavilla, P
Mejía, JC
Aydintug, AC
Chwalinska-Sadowska, H
de Ramón, E
Fernández-Nebro, A
Galeazzi, M
Valen, M
Mathieu, A
Houssiau, FD
Caro, N
Alba, P
Ramos-Casals, M
Ingelmo, M
Hughes, GRV
机构
[1] Univ Barcelona, Serv Malaties Autoimmunes, Hosp Clin,IDIBAPS, Dept Autoimmune Dis,Inst Clin Infecc & Immunol, Barcelona 08036, Catalonia, Spain
[2] St Thomas Hosp, Rayne Inst, Lupus Unit, London SE1 7EH, England
[3] Osped San Camillo De Lellis, Div Reumatol, Rome, Italy
[4] Hosp La Paz, Med Interna Serv, Madrid, Spain
[5] Ankara Univ, Sch Med, Dept Clin Immunol & Rheumatol, TR-06100 Ankara, Turkey
[6] Inst Rheumatol, Dept Connect Tissue Dis, Warsaw, Poland
[7] Hosp Reg Carlos Haya, Unidad Enfermedades Autoimmunes Sistem, Med Interna Serv, Malaga, Spain
[8] Hosp Reg Carlos Haya, Unidad Enfermedades Autoimmunes Sistem, Serv Nefrol, Malaga, Spain
[9] Hosp Clin Univ, Med Interna Serv, Malaga, Spain
[10] Hosp Clin Univ, Secc Reumatol, Malaga, Spain
[11] Univ Siena, Ist Reumatol, I-53100 Siena, Italy
[12] Haukeland Hosp, Dept Rheumatol, Bergen, Norway
[13] Univ Cagliari, Cattedra Reumatol, Cagliari, Italy
[14] Clin Univ St Luc, Serv Rheumatol, Catholic Univ Louvain, B-1200 Brussels, Belgium
关键词
D O I
10.1097/01.md.0000091181.93122.55
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In the present study, we assessed the frequency and characteristics of the main causes of morbidity and mortality in systemic lupus erythematosus (SLE) during a 10-year period and compared the frequency of early manifestations with those that appeared later in the evolution of the disease. In 1990, we started a multicenter study of 1,000 patients from 7 European countries. All had medical histories documented and underwent medical interview and routine general physical examination when entered in the study, and all were followed prospectively by the same physicians during the ensuing 10 years (1990-2000). A total of 481 (48.1%) patients presented 1 or more episodes of arthritis at any time during the 10 years, 311 (31.1%) patients had malar rash, 279 (27.9%) active nephropathy, 194 (19.4%) neurologic involvement, 166 (16.6%) fever, 163 (16.3%) Raynaud phenomenon, 160 (16.0%) serositis (pleuritis and/or pericarditis), 134 (13.4%) thrombocytopenia, and 92 (9.2%) thrombosis. When the prevalences of the clinical manifestations during the initial 5 years of follow-up (1990-1995) were compared with those during the ensuing 5 years (1995-2000), most manifestations were found to be more frequent during the initial 5 years. Of the 1,000 patients, 360 (36%) presented infections, 169 (16.9%) hypertension, 121 (12.1%) osteoporosis, and 81 (8.1%) cytopenia due to immunosuppressive agents. Twenty-three (2.3%) patients developed malignancies; the most frequent primary localizations were the uterus and the breast. Sixty-eight (6.8%) patients died, and the most frequent causes of death were similarly divided between active SLE (26.5%), thromboses (26.5%), and infections (25%). A survival probability of 92% at 10 years was found. A lower survival probability was detected in those patients who presented at the beginning of the study with nephropathy (88% versus 94% in patients without nephropathy, p = 0.045). When the causes of death during the initial 5 years of follow-up (1990-1995) were compared with those during the ensuing 5 years (1995-2000), active SLE and infections (28.9% each) appeared to be the most common causes during the initial 5 years, while thromboses (26.1%) became the most common cause of death during the last 5 years. In conclusion, most of the SLE inflammatory manifestations appear to be less common after a long-term evolution of the disease, probably reflecting the effect of therapy as well as the progressive remission of the disease in many patients. Meanwhile, a more prominent role of thrombotic events is becoming evident, affecting both morbidity and mortality in SLE.
引用
收藏
页码:299 / 308
页数:10
相关论文
共 39 条
  • [31] VARIABLES ASSOCIATED WITH DECREASED SURVIVAL IN SYSTEMIC LUPUS-ERYTHEMATOSUS
    SELEZNICK, MJ
    FRIES, JF
    [J]. SEMINARS IN ARTHRITIS AND RHEUMATISM, 1991, 21 (02) : 73 - 80
  • [32] Is there an association of malignancy with systemic lupus erythematosus? An analysis of 276 patients under long-term review
    Sultan, SM
    Ioannou, Y
    Isenberg, DA
    [J]. RHEUMATOLOGY, 2000, 39 (10) : 1147 - 1152
  • [33] SYSTEMIC LUPUS-ERYTHEMATOSUS .1. OUTCOME AND SURVIVAL - DUTCH EXPERIENCE WITH 110 PATIENTS STUDIED PROSPECTIVELY
    SWAAK, AJG
    NOSSENT, JC
    BRONSVELD, W
    VANROOYEN, A
    NIEUWENHUYS, EJ
    THEUNS, L
    SMEENK, RJT
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 1989, 48 (06) : 447 - 454
  • [34] Systemic lupus erythematosus. Disease outcome in patients with a disease duration of at least 10 years: second evaluation
    Swaak, AJG
    van den Brink, HG
    Smeenk, RJT
    Manger, K
    Kalden, JR
    Tosi, S
    Domljan, Z
    Rozman, B
    Logar, D
    Pokorny, G
    Kovacs, L
    Kovacs, A
    Vlachoyiannopoulos, PG
    Moutsopoulos, HM
    Chwalinska-Sadowska, H
    Kiss, E
    Cikes, N
    Anic, B
    Schneider, M
    Fischer, R
    Bombardieri, S
    Mosca, M
    Graninger, W
    Smolen, JS
    [J]. LUPUS, 2001, 10 (01) : 51 - 58
  • [35] SWEENEY DM, 1995, J RHEUMATOL, V22, P1478
  • [36] SPECIAL ARTICLE - THE 1982 REVISED CRITERIA FOR THE CLASSIFICATION OF SYSTEMIC LUPUS-ERYTHEMATOSUS
    TAN, EM
    COHEN, AS
    FRIES, JF
    MASI, AT
    MCSHANE, DJ
    ROTHFIELD, NF
    SCHALLER, JG
    TALAL, N
    WINCHESTER, RJ
    [J]. ARTHRITIS AND RHEUMATISM, 1982, 25 (11): : 1271 - 1277
  • [37] Tseng C, 1997, ARTHRITIS RHEUM, V40, P1626
  • [38] BIMODAL MORTALITY PATTERN OF SYSTEMIC LUPUS-ERYTHEMATOSUS
    UROWITZ, MB
    BOOKMAN, AAM
    KOEHLER, BE
    GORDON, DA
    SMYTHE, HA
    OGRYZLO, MA
    [J]. AMERICAN JOURNAL OF MEDICINE, 1976, 60 (02) : 221 - 225
  • [39] Systemic lupus erythematosus in Malaysia: A study of 539 patients and comparison of prevalence and disease expression in different racial and gender groups
    Wang, F
    Wang, CL
    Tan, CT
    Manivasagar, M
    [J]. LUPUS, 1997, 6 (03) : 248 - 253